Loading...
Hangzhou Tigermed Consulting Co., Ltd.
HNGZY•PNK
HealthcareMedical - Diagnostics & Research
$4.00
$0.00(0.00%)
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Financial Performance & Statements
Review Hangzhou Tigermed Consulting Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-10.58%
↓ 10.58%
Operating Income Growth
-73.28%
↓ 73.28%
Net Income Growth
-79.99%
↓ 79.99%
Operating Cash Flow Growth
-4.64%
↓ 4.64%
Operating Margin
7.49%
↑ 7.49%
Gross Margin
31.39%
↑ 31.39%
Net Profit Margin
5.16%
↑ 5.16%
ROE
1.62%
↑ 1.62%
ROIC
1.94%
↑ 1.94%
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Hangzhou Tigermed Consulting Co., Ltd. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.54B | $1.71B | $1.69B | $1.65B |
| Cost of Revenue | $1.26B | $1.07B | $1.03B | $1.03B |
| Gross Profit | $271.73M | $637.23M | $661.95M | $620.42M |
| Gross Profit Ratio | $0.18 | $0.37 | $0.39 | $0.38 |
| R&D Expenses | $66.29M | $47.40M | $58.78M | $63.91M |
| SG&A Expenses | -$354.11M | $542.77M | $237.31M | $234.17M |
| Operating Expenses | $692.31M | $239.31M | $296.76M | $305.83M |
| Total Costs & Expenses | $1.96B | $1.31B | $1.33B | $1.34B |
| Interest Income | $0.00 | $0.00 | $26.65M | $0.00 |
| Interest Expense | $0.00 | $0.00 | $5.81M | $0.00 |
| Depreciation & Amortization | $0.00 | -$61.41M | $90.19M | $46.26M |
| EBITDA | -$288.35M | $336.52M | $379.63M | $352.86M |
| EBITDA Ratio | -$0.19 | $0.20 | $0.22 | $0.21 |
| Operating Income | -$420.58M | $397.93M | $365.19M | $314.59M |
| Operating Income Ratio | -$0.27 | $0.23 | $0.22 | $0.19 |
| Other Income/Expenses (Net) | -$2.03M | -$954682.00 | -$37.46M | $47.77M |
| Income Before Tax | -$422.60M | $396.97M | $283.63M | $362.36M |
| Income Before Tax Ratio | -$0.28 | $0.23 | $0.17 | $0.22 |
| Income Tax Expense | $32.70M | $51.42M | $82.72M | $49.79M |
| Net Income | -$408.29M | $320.58M | $257.78M | $235.07M |
| Net Income Ratio | -$0.27 | $0.19 | $0.15 | $0.14 |
| EPS | -$0.47 | $0.37 | $0.30 | $0.27 |
| Diluted EPS | -$0.47 | $0.37 | $0.30 | $0.27 |
| Weighted Avg Shares Outstanding | $862.007M | $864.95M | $864.95M | $872.44M |
| Weighted Avg Shares Outstanding (Diluted) | $862.007M | $864.95M | $864.95M | $872.44M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan